Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.

Vicente Escudero-VilaplanaRoberto Collado-BorrellMaria Del Monte-MillánAngela Hoyo-MuñozPatricia Gómez Martínez-SagreraJose Luis Revuelta-HerreroBelen Marzal-AlfaroEva Gonzalez-HabaSara López-Tarruella CoboYolanda Jerez GilarranzAna HerranzMaria SanjurjoMiguel Martin

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2021)

More than a third of patients in treatment with OAAs presented diarrhea (any grade), and 22.1% of stools were semi-liquid/liquid. In multivariate analysis, taking the OAA on an empty stomach was associated with a statistically significant increase in the incidence of diarrhea.

Keyphrases

irritable bowel syndrome
clinical practice
end stage renal disease
clostridium difficile
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
cancer therapy
data analysis
drug delivery
patient reported
replacement therapy
endoscopic submucosal dissection